DE60235632D1 - Bicyclische verbindung, deren herstellung und verwendung - Google Patents

Bicyclische verbindung, deren herstellung und verwendung

Info

Publication number
DE60235632D1
DE60235632D1 DE60235632T DE60235632T DE60235632D1 DE 60235632 D1 DE60235632 D1 DE 60235632D1 DE 60235632 T DE60235632 T DE 60235632T DE 60235632 T DE60235632 T DE 60235632T DE 60235632 D1 DE60235632 D1 DE 60235632D1
Authority
DE
Germany
Prior art keywords
preparation
bicyclic compound
bicyclic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235632T
Other languages
English (en)
Inventor
Mitsuru Shiraishi
Masanori Baba
Katsuji Aikawa
Naoyuki Kanzaki
Masaki Seto
Yuji Iizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tobira Therapeutics Inc
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Application granted granted Critical
Publication of DE60235632D1 publication Critical patent/DE60235632D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/16—Eight-membered rings
    • C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
DE60235632T 2001-08-08 2002-08-07 Bicyclische verbindung, deren herstellung und verwendung Expired - Lifetime DE60235632D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001240750 2001-08-08
JP2002066809 2002-03-12
PCT/JP2002/008043 WO2003014105A1 (en) 2001-08-08 2002-08-07 Bicyclic compound, production and use as hiv inhibitors

Publications (1)

Publication Number Publication Date
DE60235632D1 true DE60235632D1 (de) 2010-04-22

Family

ID=26620186

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60235632T Expired - Lifetime DE60235632D1 (de) 2001-08-08 2002-08-07 Bicyclische verbindung, deren herstellung und verwendung

Country Status (14)

Country Link
US (7) US7371772B2 (de)
EP (3) EP2206702B1 (de)
JP (4) JP4316203B2 (de)
AR (1) AR034985A1 (de)
AT (2) ATE460406T1 (de)
AU (1) AU2002328092A1 (de)
CA (2) CA2459172C (de)
DE (1) DE60235632D1 (de)
DK (2) DK2206702T3 (de)
ES (2) ES2376855T3 (de)
HK (1) HK1142886A1 (de)
PE (1) PE20030329A1 (de)
PT (2) PT1423376E (de)
WO (1) WO2003014105A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2206702T3 (da) * 2001-08-08 2012-02-13 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
WO2003076411A1 (fr) * 2002-03-12 2003-09-18 Takeda Pharmaceutical Company Limited Procede de production d'un derive sulfoxyde actif sur le plan optique
WO2004069834A1 (ja) * 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 三環性化合物、その製造方法および用途
EP1593680A4 (de) * 2003-02-07 2008-05-07 Takeda Pharmaceutical Pyridinderivate mit kondensiertem ring, verfahren zu deren herstellung und verwendung
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
ES2425937T3 (es) * 2004-03-24 2013-10-18 Takeda Pharmaceutical Company Limited Estabilizante de emulsión
EP1728505B1 (de) * 2004-03-24 2014-06-04 Takeda Pharmaceutical Company Limited Zubereitung mit erhöhtem gehalt
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
JPWO2006059716A1 (ja) * 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
KR20110097770A (ko) * 2008-10-17 2011-08-31 인베이스크 테라퓨틱, 인크. 레닌-안지오텐신 알도스테론 시스템(ｒａａｓ) 관련 질병 치료용 조성물 및 방법
EP3133070B1 (de) 2009-11-27 2019-08-14 Genzyme Corporation Eliglustat (genz 112638) als inhibitor der glucosylceramidsynthase zur verwendung in einem verfahren zur behandlung von fabry's oder gaucher's erkrankung, wobei das verfahren die anpassung der individuellen thearapeutischen dosis an den p-450 stoffwechsel des patienten umfasst
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
WO2012047630A2 (en) * 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
SG11201607859SA (en) 2014-03-21 2016-10-28 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis
WO2015187663A1 (en) * 2014-06-02 2015-12-10 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
RU2723559C2 (ru) 2014-09-12 2020-06-16 Тобира Терапьютикс, Инк. Комбинированная терапия с применением препарата ценикривирок для лечения фиброза
RU2725888C2 (ru) * 2014-12-23 2020-07-07 Тобира Терапьютикс, Инк. Способ получения ценикривирока и родственных аналогов
EP3256124B1 (de) 2015-02-10 2020-12-23 Tobira Therapeutics, Inc. Zusammensetzung enthaltend cenicriviroc und fumarsäure zur behandlung von akuten leberverletzungen oder peritonitis
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
KR20190039087A (ko) * 2016-06-21 2019-04-10 토비라 쎄라퓨틱스, 인크. 정제된 세니크리비록 및 세니크리비록을 제조하기 위한 정제된 중간체
WO2018045043A1 (en) * 2016-08-31 2018-03-08 Tobira Therapeutics, Inc. Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
CN110023286B (zh) 2016-12-09 2021-06-01 南京明德新药研发有限公司 作为ccr2/ccr5受体拮抗剂的联苯化合物
AU2018223976B2 (en) 2017-02-24 2023-08-17 Genfit Pharmaceutical compositions for combination therapy
WO2019149089A1 (zh) 2018-02-02 2019-08-08 四川科伦博泰生物医药股份有限公司 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
CN113412261A (zh) * 2019-04-08 2021-09-17 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
EP3988098B1 (de) * 2019-06-24 2024-07-24 Wuxi Life Fountain Biotech Co., Ltd. Heterocycloalkylverbindungen als ccr2/ccr5-antagonisten
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
JP7502467B2 (ja) * 2020-05-22 2024-06-18 メッドシャイン ディスカバリー インコーポレイテッド ピリジン系誘導体及びその使用
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
CA2191980A1 (en) 1994-07-04 1996-01-18 Takashi Sohda Phosphonic acid compounds, their production and use
RU2167649C2 (ru) 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
ATE270552T1 (de) 1997-10-20 2004-07-15 Dainippon Pharmaceutical Co Von tetrahydropyrrolo (1,2-a) pyrazin-4-spiro-3'- pyrrolidine stabilisierte zusammenstellung
KR20010032841A (ko) 1997-12-19 2001-04-25 다케다 야쿠힌 고교 가부시키가이샤 아닐리드 유도체를 함유하는 ｃｃｒ5 길항용 약학 조성물
US6096780A (en) * 1998-08-20 2000-08-01 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use
CA2244097A1 (en) 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
CA2353635A1 (en) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof
EP1172097B1 (de) 1999-04-12 2004-09-08 Shionogi & Co., Ltd. Verfahren zur herstellung von arzneimitteln eines basischen hydrophoben wirkstoffs
JP2001026586A (ja) 1999-05-07 2001-01-30 Takeda Chem Ind Ltd 環状化合物およびその用途
EP1211239A4 (de) 1999-09-06 2003-08-06 Takeda Chemical Industries Ltd Verfahren zur herstellung von 2,3-dihydroazepin-derivaten
DK2206702T3 (da) * 2001-08-08 2012-02-13 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
WO2003076411A1 (fr) 2002-03-12 2003-09-18 Takeda Pharmaceutical Company Limited Procede de production d'un derive sulfoxyde actif sur le plan optique
ES2425937T3 (es) * 2004-03-24 2013-10-18 Takeda Pharmaceutical Company Limited Estabilizante de emulsión
EP1728505B1 (de) * 2004-03-24 2014-06-04 Takeda Pharmaceutical Company Limited Zubereitung mit erhöhtem gehalt
JPWO2006059716A1 (ja) * 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
WO2008030853A2 (en) 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
PE20140406A1 (es) 2010-11-18 2014-04-16 Univ Yale Moleculas bifuncionales con actividad de reclutamiento de anticuerpos y actividad inhibitoria inicial contra el virus de la inmunodeficiencia humana
WO2013000922A1 (en) 2011-06-27 2013-01-03 Universite Pierre Et Marie Curie (Paris 6) Ccr2 antagonist peptides
BR112015028644A2 (pt) 2013-05-15 2017-07-25 Tobira Therapeutics Inc composições de cenicriviroc e métodos de criação e uso do mesmo
SG11201607859SA (en) 2014-03-21 2016-10-28 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis
RU2725888C2 (ru) 2014-12-23 2020-07-07 Тобира Терапьютикс, Инк. Способ получения ценикривирока и родственных аналогов
EP3256124B1 (de) 2015-02-10 2020-12-23 Tobira Therapeutics, Inc. Zusammensetzung enthaltend cenicriviroc und fumarsäure zur behandlung von akuten leberverletzungen oder peritonitis

Also Published As

Publication number Publication date
JP2009209154A (ja) 2009-09-17
ATE460406T1 (de) 2010-03-15
WO2003014105A1 (en) 2003-02-20
EP1423376A1 (de) 2004-06-02
US20200297700A1 (en) 2020-09-24
US8183273B2 (en) 2012-05-22
HK1142886A1 (en) 2010-12-17
US20120232028A1 (en) 2012-09-13
US20090030032A1 (en) 2009-01-29
JP2007084578A (ja) 2007-04-05
CA2607992A1 (en) 2003-02-20
PE20030329A1 (es) 2003-05-12
US8741943B2 (en) 2014-06-03
AR034985A1 (es) 2004-03-24
JP4358851B2 (ja) 2009-11-04
US20080161287A1 (en) 2008-07-03
EP2206702B1 (de) 2011-12-28
JP5275148B2 (ja) 2013-08-28
ES2376855T3 (es) 2012-03-20
ES2339340T3 (es) 2010-05-19
PT1423376E (pt) 2010-04-12
US7371772B2 (en) 2008-05-13
JP2003335776A (ja) 2003-11-28
EP2206702A1 (de) 2010-07-14
ATE539062T1 (de) 2012-01-15
JP4316203B2 (ja) 2009-08-19
US10045968B2 (en) 2018-08-14
CA2459172C (en) 2011-07-05
PT2206702E (pt) 2012-02-03
US20040259876A1 (en) 2004-12-23
US20190038604A1 (en) 2019-02-07
EP1889839A1 (de) 2008-02-20
US20160008326A1 (en) 2016-01-14
WO2003014105A9 (en) 2003-11-20
DK2206702T3 (da) 2012-02-13
JP2013136629A (ja) 2013-07-11
EP1889839B1 (de) 2013-11-06
CA2459172A1 (en) 2003-02-20
US8362058B2 (en) 2013-01-29
DK1423376T3 (da) 2010-06-28
AU2002328092A1 (en) 2003-02-24
EP1423376B1 (de) 2010-03-10

Similar Documents

Publication Publication Date Title
DE60235632D1 (de) Bicyclische verbindung, deren herstellung und verwendung
EE200300544A (et) 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
HK1078266A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
DE60336907D1 (de) Spirobifluorenderivate, deren herstellung und deren verwendung
DE60208622D1 (de) Siliciumoxidpulver und dessen Herstellung
DE60235547D1 (de) En daraus, deren herstellung und verwendung
DE60203917D1 (de) Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate, deren herstellung und deren therapeutische verwendung
DE60200010D1 (de) Mehrstellungsfluggastsitz
DE50209483D1 (de) Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
DE60209779D1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DE60200427D1 (de) Vernetzbare Fluorelastomerzusammensetzungen, ihre Herstellung und Verwendung
DE69928140D1 (de) Antipicornavirale Verbindungen, deren Herstellung und Verwendung
DE60130834D1 (de) Zusammensetzungen gegen schlechte Gerüche, deren Herstellung und Verwendung
DE60220258D1 (de) Derivate von quinolyl-propyl-piperidine, deren herstellung und die sie enthaltenden zusamensetzungen
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
DE60015004D1 (de) Russ, seine Herstellung und Verwendungen
DE60209431D1 (de) Sitzstruktur
DE60216345D1 (de) Gummimischung und deren Verwendung
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
DE60005690D1 (de) Titanverbindungen, deren herstellung und verwendung
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
ATA20102001A (de) Uv-resistenter, thermohärtbarer aminoplastverbund, dessen herstellung und verwendung
FR2821754B1 (fr) Descenceur autobloquant
DE50203525D1 (de) Tetrahydroisochinoline, ihre herstellung und verwendung als schmerzmittel

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TOBIRA THERAPEUTICS,INC., MANALAPAN, N.J., US

8364 No opposition during term of opposition